Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.cgh.2007.05.004
DC FieldValue
dc.titleReport of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B
dc.contributor.authorKeeffe, E.B.
dc.contributor.authorZeuzem, S.
dc.contributor.authorKoff, R.S.
dc.contributor.authorDieterich, D.T.
dc.contributor.authorEsteban-Mur, R.
dc.contributor.authorGane, E.J.
dc.contributor.authorJacobson, I.M.
dc.contributor.authorLim, S.G.
dc.contributor.authorNaoumov, N.
dc.contributor.authorMarcellin, P.
dc.contributor.authorPiratvisuth, T.
dc.contributor.authorZoulim, F.
dc.date.accessioned2016-11-17T08:39:30Z
dc.date.available2016-11-17T08:39:30Z
dc.date.issued2007-08
dc.identifier.citationKeeffe, E.B., Zeuzem, S., Koff, R.S., Dieterich, D.T., Esteban-Mur, R., Gane, E.J., Jacobson, I.M., Lim, S.G., Naoumov, N., Marcellin, P., Piratvisuth, T., Zoulim, F. (2007-08). Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B. Clinical Gastroenterology and Hepatology 5 (8) : 890-897. ScholarBank@NUS Repository. https://doi.org/10.1016/j.cgh.2007.05.004
dc.identifier.issn15423565
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/130637
dc.description.abstractAn international group of experienced hepatologists and virologists conducted a single-day workshop to review the management of patients with chronic hepatitis B receiving treatment with oral nucleosides or nucleotides. Guidelines regarding on-treatment management and available published data on the importance of serum hepatitis B virus (HBV) DNA as a marker of outcomes were reviewed. On-treatment monitoring strategies to define early virologic responses that might be predictive of better outcomes and a reduced risk of viral resistance were proposed for further study. This treatment plan, labeled the roadmap concept, recommends monitoring of serum HBV DNA levels to identify outcomes of therapy. Primary treatment failure was defined as a reduction of serum HBV DNA levels by less than 1 log10 IU/mL from baseline at week 12. Measurement of the HBV DNA level at week 24 was considered essential to characterize virologic responses as complete, partial, or inadequate. Complete virologic response was defined as negative HBV DNA by a sensitive assay (
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.cgh.2007.05.004
dc.sourceScopus
dc.typeReview
dc.contributor.departmentMEDICINE
dc.description.doi10.1016/j.cgh.2007.05.004
dc.description.sourcetitleClinical Gastroenterology and Hepatology
dc.description.volume5
dc.description.issue8
dc.description.page890-897
dc.description.codenCGHLA
dc.identifier.isiut000248714400004
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

249
checked on Nov 30, 2021

WEB OF SCIENCETM
Citations

214
checked on Nov 30, 2021

Page view(s)

71
checked on Dec 2, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.